Kristi-Jo M Noel

Kristi-Jo M. Noel supports the procurement mission of the National Cancer Institute by managing complex research and development acquisitions aligned with the agency’s mission to accelerate cancer diagnostics and precision medicine. Though her official title is not specified, her procurement activities center on high-value scientific services, including laboratory infrastructure support, genomic analysis platforms, and translational research tools. She oversees contracts that enable cutting-edge biomedical innovation, ensuring that NCI’s research priorities are met through agile, technically rigorous acquisition strategies that prioritize scientific capability over cost alone. Her primary contractor relationships are dominated by Roche Diagnostics Corporation, reflecting a consistent reliance on industry leaders with proven expertise in molecular diagnostics, assay development, and clinical research support systems. These partnerships are characterized by long-term, performance-based engagements that emphasize technical validation, regulatory compliance, and scalable infrastructure—key requirements for supporting NCI’s large-scale research initiatives. Her contracting patterns indicate a preference for established, high-capacity vendors capable of delivering integrated solutions across multiple research domains. Noel’s procurement portfolio reflects no set-aside preferences, with 100% of awards issued under full and open competition. This indicates a strategic focus on technical excellence and scientific capability as the primary selection criteria, rather than socioeconomic objectives. While small business participation is not formally prioritized in her award patterns, her approach aligns with NCI’s mission-critical need for proven, scalable solutions in time-sensitive research environments. Her acquisitions are overwhelmingly concentrated in NAICS 541715—Research and Development in the Physical, Engineering, and Life Sciences—with a secondary focus on 541990 for specialized scientific and technical services. She procures advanced instrumentation, bioinformatics platforms, clinical trial support systems, and laboratory automation technologies, demonstrating deep domain expertise in oncology research infrastructure and translational science enablement.